About: Aspectos y consideraciones generales en la Enfermedad Inflamatoria Intestinal durante la pandemia por COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Aspectos y consideraciones generales en la Enfermedad Inflamatoria Intestinal durante la pandemia por COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Aspectos y consideraciones generales en la Enfermedad Inflamatoria Intestinal durante la pandemia por COVID-19
Creator	De León-Rendón, J Hurtado-Salazar, C Yamamoto, Jesús Yamamoto-Furusho, J
Source	Elsevier; Medline; PMC; WHO
abstract	Resumen Hasta este momento la evidencia disponible sugiere que los pacientes con EII no tienen un mayor riesgo de desarrollar COVID-19. En pacientes con remisión de la EII: los 5-aminosalicilatos (5-ASA) no incrementan el riesgo de infección y se deben continuar sin necesidad de suspenderlos o disminuir la dosis; los fármacos inmunomoduladores como las tiopurinas y metotrexato deben continuarse sin modificar las dosis (a considerar en el paciente con infección por SARS-CoV-2 positiva), y en relación a cualquier tipo de terapia biológica no deberá suspenderse a menos que existan datos de COVID-19. En aquellos pacientes con actividad de la EII: Se deberá optimizar la dosis de 5-ASA en administración oral y/o tópica en caso de recaída de la enfermedad; considerar el uso de budesonida MMX en casos de actividad leve a moderada con el fin de evitar uso de esteroides sistémicos; los esteroides sistémicos deben evitarse en la medida de lo posible ya que dosis mayores de 20 mg al día ejercen efecto inmunosupresor el cual pudiera aumentar la susceptibilidad a cualquier tipo de infección incluyendo COVID-19; evitar el uso combinado de tiopurinas con esteroides y/o agentes anti-TNF ya que puede incrementar el riesgo de infecciones incluyendo el COVID-19 y finalmente el tratamiento biológico con agentes en contra del factor de necrosis tumoral alfa (anti-TNF alfa) o de cualquier otro mecanismo de acción como anti-integrinas o anti-interleucinas deberán de suspenderse en caso de documentarse infección por COVID-19 y podrán reiniciarse en cuanto haya cedido el proceso infeccioso. Abstract So far, available evidence suggests that patients with inflammatory bowel disease (IBD) are not at greater risk for COVID-19 infection. In regard to patients with IBD remission: 5-aminosalycylates (5-ASAs) do not increase the risk for infection and should be continued. There is no need to suspend them or lower the dose. Immunomodulating drugs, such as thiopurines and methotrexate, should be continued, without modifying doses (even in patients with positive SARS-CoV-2 infection). No type of biologic therapy should be suspended, unless patients become infected with COVID-19. Regarding patients with IBD activity: the oral and/or topical 5-ASA dose should be optimized in cases of disease relapse. Budesonide MMX should be considered in cases of mild-to-moderate activity, to avoid systemic steroid use. Systemic steroids should be avoided whenever possible because doses above 20 mg per day have an immunosuppressive effect, which could increase susceptibility to any type of infection, including COVID-19. The combined use of thiopurines with steroids and/or tumor necrosis factor (TNF) monoclonal antibodies should also be avoided because those combinations can increase the risk for infections, including COVID-19. Finally, biologic treatment with anti-TNF-alpha agents or any other mechanism of action, such as anti-integrins or anti-interleukins, should be suspended if patients become infected with COVID-19. The drugs can be restarted once the infectious process is resolved.
has issue date	2020-05-23(xsd:dateTime)
bibo:doi	10.1016/j.rgmx.2020.05.001
bibo:pmid	32536480
has license	els-covid
sha1sum (hex)	0e54b576dd53254615ac56211e2421646cbc3b3a
schema:url	https://doi.org/10.1016/j.rgmx.2020.05.001
resource representing a document's title	Aspectos y consideraciones generales en la Enfermedad Inflamatoria Intestinal durante la pandemia por COVID-19
has PubMed Central identifier	PMC7245301
has PubMed identifier	32536480
schema:publication	Rev Gastroenterol Mex
resource representing a document's body	covid:0e54b576dd53254615ac56211e2421646cbc3b3a#body_text
is schema:about of	named entity 'deben' named entity 'anti-TNF' named entity 'ASA' named entity 'como' named entity 'POR' named entity 'contra' named entity 'proceso' named entity 'sin' named entity 'como' named entity 'deben' named entity 'alfa' named entity 'SARS-CoV-2' named entity 'Page 2' named entity 'COVID-19' named entity 'Aspects' named entity 'MMX' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'COVID-19 pandemic' named entity 'COVID-19' named entity 'el 11' named entity 'CUCI' named entity 'el 15' named entity 'la provincia' named entity 'diabetes mellitus' named entity 'La respuesta' named entity 'SARS-CoV-2' named entity 'Cilag' named entity 'usan' named entity 'SARS-CoV-1' named entity 'infección' named entity 'infección' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'la entrada' named entity 'adalimumab' named entity 'mismo' named entity 'infliximab' named entity 'Dada' named entity 'guantes' named entity 'la respuesta' named entity 'ACE2' named entity 'el presente' named entity 'Bristol Myers Squib' named entity 'el equipo' named entity 'SARS-CoV-2' named entity 'infección' named entity 'infliximab' named entity 'usan' named entity 'ustekinumab' named entity 'COVID-19' named entity 'Pfizer' named entity 'vedolizumab' named entity 'ACE2' named entity 'CUCI' named entity 'COVID-19' named entity 'vedolizumab' named entity 'SARS-CoV-2' named entity 'infliximab' named entity 'ustekinumab' named entity 'golimumab' named entity 'Como' named entity 'tofacitinib' named entity 'Abbvie' named entity 'las manos' named entity 'tofacitinib' named entity 'CUCI' named entity 'COVID-19' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'CUCI' named entity 'Pfizer' named entity 'COVID-19' named entity 'China' named entity 'la Sociedad' named entity 'SARS-CoV-2' named entity 'el equipo' named entity 'probablemente'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software